MNG248
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.462
- HEDGEHOG_SIGNALING+0.428
- INTERFERON_ALPHA_RESPONSE+0.407
- ALLOGRAFT_REJECTION+0.381
- MITOTIC_SPINDLE+0.372
- INTERFERON_GAMMA_RESPONSE+0.365
- KRAS_SIGNALING_UP+0.311
- ANGIOGENESIS+0.302
- TGF_BETA_SIGNALING+0.301
- APICAL_SURFACE+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.397
- P53_PATHWAY-0.226
- PEROXISOME-0.214
- MYC_TARGETS_V1-0.200
- MYC_TARGETS_V2-0.192
- GLYCOLYSIS-0.149
- ESTROGEN_RESPONSE_EARLY-0.145
- FATTY_ACID_METABOLISM-0.137
- XENOBIOTIC_METABOLISM-0.128
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.127
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG530 | — | — | 0.829 |
| 2 | TCGA-FD-A3SP-01A-31R-A22U-07 | — | — | 0.817 |
| 3 | TCGA-CR-7377-01A-11R-2016-07 | — | — | 0.811 |
| 4 | TCGA-CR-7382-01A-11R-2132-07 | — | — | 0.803 |
| 5 | TCGA-85-8287-01A-11R-2296-07 | — | cohortSQ1 | 0.798 |
| 6 | SRR5088879 | — | — | 0.798 |
| 7 | TCGA-56-8625-01A-11R-2403-07 | — | cohortSQ1 | 0.793 |
| 8 | TCGA-56-8309-01A-11R-2296-07 | — | cohortSQ1 | 0.791 |
| 9 | BSR_10_0229_A4_S93 | — | D | 0.785 |
| 10 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.783 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.462 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.428 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.407 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.381 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.372 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.365 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.311 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.302 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.301 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| UV_RESPONSE_DN | 0.282 | Inavolisib | — uncovered |
| MYOGENESIS | 0.231 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.228 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.208 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.184 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.175 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.138 | Inavolisib | — uncovered |
| HYPOXIA | 0.133 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.123 | Idelalisib | — uncovered |